Drug Trial Radar · NCT06724640
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of VH4011499 Compared to Placebo in Adults Without HIV
Last checked: Nov 20, 2026Latest source record: Oct 29, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
168
Planned (sponsor's estimate)
Start
Dec 16, 2024
Primary completion
Aug 16, 2028
Study completion Aug 16, 2028
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- First posted
- Dec 9, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to investigate safety, pharmacokinetics and tolerability following single ascending dose (SAD) and multiple ascending doses (MAD) of VH4011499 administered subcutaneously (SC) and intramuscularly (IM) in participants without HIV.
Conditions
- HIV Infections
Interventions
VH4011499 low dose InjectionDrug
VH4011499 low dose Injection will be administered subcutaneously and/or intramuscularly.
VH4011499 high dose InjectionDrug
VH4011499 high dose Injection will be administered subcutaneously and/or intramuscularly.
PlaceboDrug
Placebo Injection will be administered either subcutaneously or intramuscularly.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs), including Injection Site Reaction (ISR) AEs, as per severity of Grade 2-5 using the DAIDS grading scaleTime frame: Up to Week 78
- Area under the plasma-concentration time curve from time zero to infinity (AUC0-inf) of VH4011499 for SAD groupTime frame: Up to Week 78
- Area under the plasma concentration vs time curve (AUC0-tau) for MAD groupTime frame: Up to Week 78
- Maximum observed plasma concentration (Cmax) of VH4011499Time frame: Up to Week 78
- Time to maximum observed plasma concentration (tmax) of VH4011499Time frame: Up to Week 78
- Apparent terminal half-life (t1/2) of VH4011499Time frame: Up to Week 78
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Las Vegas, Nevada · Recruiting
GSK Investigational Site
Austin, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.